title: Ebola vaccine and treatment.
abstract: Filoviruses (Ebola and Marburg viruses) cause severe hemorrhagic fever in humans and nonhuman primates. No effective prophylaxis or treatment for filovirus diseases is yet commercially available. The recent outbreak of Ebola virus disease in West Africa has accelerated efforts to develop anti-Ebola virus prophylaxis and treatment, and unapproved drugs were indeed used for the treatment of patients during the outbreak. This article reviews previous researches and the latest topics on vaccine and therapy for Ebola virus disease.
authors.affiliation: Hokkaido University Research Center for Zoonosis Control.
authors.forename: Ayato
authors.initials: A
authors.lastname: Takada
mesh_terms: D000354:Africa, Western / Q000453:epidemiology; D000595:Amino Acid Sequence; D000818:Animals; D002477:Cells / Q000821:virology; D004196:Disease Outbreaks; D055808:Drug Discovery; D046129:Ebola Vaccines / Q000627:therapeutic use; D029043:Ebolavirus / Q000235:genetics / Q000254:growth & development / Q000472:pathogenicity*; D019142:Hemorrhagic Fever, Ebola / Q000188:drug therapy* / Q000453:epidemiology / Q000517:prevention & control* / Q000821:virology; D054884:Host-Pathogen Interactions; D006801:Humans; D008562:Membrane Glycoproteins / Q000737:chemistry / Q000502:physiology; D010802:Phylogeny; D014774:Virulence
chemical_list: D046129:Ebola Vaccines; D008562:Membrane Glycoproteins